S.N. 10/554,409 Atty. Docket: 1768-139

Page 3

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-21. (Cancelled)


22. (Currently Amended) A recombinant Fel d 1 fusion product comprising a Fel d 1 chain 1, a Fel d 1 chain 2, wherein the Fel d 1 chain 1 comprises the amino acid sequence set forth in SEQ ID NO: 1 or a variant thereof, wherein Fel d 1 chain 2 comprises (i) the amino acid sequence set forth in SEQ ID NO: 2 or a variant thereof or (ii) the amino acid sequence set forth in SEQ ID NO: 3, wherein the N-terminus of the Fel d 1 chain 1 is in peptide linkage with the C-terminus of the Fel d 1 chain 2, wherein the variant of the amino acid sequence set forth in SEQ ID NO:1 is selected from the group consisting of Lys29Arg, Lys 29Asn and Val33Ser, and wherein the variant of the amino acid sequence set forth in SEQ ID NO:2 is selected from the group consisting of Asn19Ser, Gly20 Leu, ile55Val, Arg57Lys, Val58Phe, Glu69Val, Tyr72Asp, Gln79Glu and Asn88Lys.

and a linker consisting of selected from a carbon nitrogen bond or a peptide linker consisting of 1 to 9 amino acid residues which links the N-terminal amino acid of one chain to the C-terminal amino acid of the other chain.

- 23. (Canceled)
- 24. (Canceled)
- 25. (Canceled)

S.N. 10/554,409 Atty. Docket: 1768-139

Page 4



(Previously presented) A fusion product as claimed in claim 22, wherein

the chain 1 and the chain 2 are covalently bonded together by one or more disulfide

26.

27.

28.

29

30.

(Canceled)

(Canceled)

bridges into an antiparallel arrangement.

(Canceled)

(Canceled)

Page 5

and/or the homodimer as claimed in claim 33 and a pharmaceutically acceptable carrier, excipient or diluent.

- 38. (Previously presented) A kit for the diagnosis of cat allergy comprising the fusion product as claimed in claim 22 and/or the homodimer as claimed in claim 33 and instructions for use of the kit.
- 39. (Withdrawn) A method for diagnosing cat allergy comprising the step of combining a sample taken from a subject with the fusion product as claimed in claim 22, the homodimer as claimed in claim 33, or a combination thereof.
- (Withdrawn) A process for preparing a fusion product as claimed in claim
 comprising the step of culturing the host cell as claimed in claim 36 in a suitable medium.
 - 41. (Canceled)
- 42. (New) The fusion product of claim 22, wherein the Fel d 1 chain 2 further has a methionine residue on the N-terminus.
- 43. (New) The fusion product of claim 22, wherein the Fel d 1 chain 1 further has the sequence Leu-Glu-(His)₆ on the C-terminus.
- 44. (New) The fusion product of claim 42, wherein the Fel d 1 chain 1 further has the sequence Leu-Glu-(His) $_6$ on the C-terminus.
- 45. (New) The fusion product of claim 44, wherein the fusion product has the amino acid sequence set forth in SEQ ID NO: 4.

S.N. 10/554,409

Atty. Docket: 1768-139

Page 6

46. (New) A pharmaceutical composition comprising an immunotherapeutically effective amount of the fusion product as claimed in claim 45 and a pharmaceutically acceptable carrier, excipient or diluent.

47. (New) A kit for the diagnosis of cat allergy comprising the fusion product as claimed in claim 45 and instructions for use of the kit.